<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04334811</url>
  </required_header>
  <id_info>
    <org_study_id>STU-2019-1023</org_study_id>
    <nct_id>NCT04334811</nct_id>
  </id_info>
  <brief_title>Stereotactic Ablative Radiotherapy (SAbR) for Treatment of Ventricular Tachycardia (VT) Refractory Standard Invasive Ablation Techniques</brief_title>
  <official_title>Stereotactic Ablative Radiotherapy (SAbR) for Treatment of Ventricular Tachycardia (VT) Refractory Standard Invasive Ablation Techniques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical efficacy and safety of stereotactic&#xD;
      ablative radiotherapy (SAbR), also known as stereotactic body radiation therapy (SBRT), for&#xD;
      treatment of ventricular tachycardia (VT) requiring implantable cardioverter defibrillator&#xD;
      (ICD) treatments in patients with VT refractory to standard invasive ablation techniques. We&#xD;
      hypothesized that SAbR is effective in suppressing sustained VT and reducing ICD treatments&#xD;
      in this group of patients and is associated with acceptably low risk of serious&#xD;
      complications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2022</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary efficacy outcome of ICD (implantable cardioverter-defibrillator) Treatment</measure>
    <time_frame>6 months</time_frame>
    <description>Number of episodes of ICD (implantable cardioverter-defibrillator) treatment (including both ATP and shock) per month; comparing 6 months before and after SAbR (excluding the first 2-week blanking period post SAbR).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Tachycardia, Ventricular</condition>
  <arm_group>
    <arm_group_label>Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic ablative radiotherapy</intervention_name>
    <description>Stereotactic ablative radiotherapy (SAbR) delivers of a potent, ablative or nearly ablative dose of radiation in oligofractions (ie, five or fewer fractions) primarily to create a compact dose delivered accurately to the intended target with steep gradients in all directions (geometric avoidance) and avoid damaging normal tissues.</description>
    <arm_group_label>Arm</arm_group_label>
    <other_name>SAbR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  Have an ICD implanted &gt; 6 months and all VT episodes in the past 6 months are&#xD;
             available in device memory.&#xD;
&#xD;
          -  Within the past 3 months, the patient has at least one episode of symptomatic&#xD;
             monomorphic VT that requires ICD treatment (anti-tachycardia pacing and/or ICD shock)&#xD;
             or was sustained/incessant but falls under ICD treatment zone. These VT episodes must&#xD;
             occur after at least one standard invasive VT ablation or occur in a patient that is&#xD;
             clinically deemed not eligible to the standard VT ablation procedure.&#xD;
&#xD;
          -  Two independent cardiac electrophysiologists reviewed the case and agreed that the&#xD;
             patient would benefit from suppression of these VT episodes but there is no optimal&#xD;
             invasive VT ablation or antiarrhythmic drug options.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has contraindication to receive SAbR or VT clinically deemed not suitable for SAbR.&#xD;
&#xD;
          -  Is pregnant&#xD;
&#xD;
          -  Has severe co-morbid medical condition or terminal illness and is unlikely to survive&#xD;
             more than 6 months regardless of VT status based on clinical judgement by treating or&#xD;
             enrolling physicians.&#xD;
&#xD;
          -  On potent immunosuppressive therapy (e.g., post organ transplant)&#xD;
&#xD;
          -  Has severe collagen vascular disorder with organ involvement&#xD;
&#xD;
          -  Not willing or not able to consent to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>james Daniel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Hardee, MS</last_name>
    <phone>2146458525</phone>
    <email>Sarah.Hardee@UTSouthwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>KAJAL DESAI, MS</last_name>
    <phone>2146458525</phone>
    <email>Kajal.Desai@UTSouthwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>James Daniels</last_name>
      <phone>214-645-8525</phone>
      <email>James.Daniels@UTSouthwestern.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>James Daniels</investigator_full_name>
    <investigator_title>ASSOC PROFESSOR</investigator_title>
  </responsible_party>
  <keyword>heart</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

